Squarepoint
CRSP icon

Squarepoint’s CRISPR Therapeutics CRSP Stock Holding History

Squarepoint’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$485K Sell
10,200
-40,100
-80% -$2.12M ﹤0.01% 3354
2025
Q4 		$2.64M Sell
50,300
-14,900
-23% -$892K ﹤0.01% 1867
2025
Q3 		$4.23M Buy
65,200
+48,300
+286% +$2.77M ﹤0.01% 1566
2025
Q2 		$822K Sell
16,900
-4,700
-22% -$182K ﹤0.01% 2836
2025
Q1 		$735K Sell
21,600
-46,200
-68% -$1.96M ﹤0.01% 2921
2024
Q4 		$2.67M Buy
67,800
+48,000
+242% +$2.27M ﹤0.01% 2164
2024
Q3 		$930K Sell
19,800
-9,800
-33% -$497K ﹤0.01% 2660
2024
Q2 		$1.6M Sell
29,600
-25,600
-46% -$1.48M ﹤0.01% 2211
2024
Q1 		$3.76M Buy
55,200
+23,200
+73% +$1.66M 0.01% 1658
2023
Q4 		$2M Sell
32,000
-39,900
-55% -$2.21M ﹤0.01% 1997
2023
Q3 		$3.26M Sell
71,900
-43,400
-38% -$2.24M 0.01% 1458
2023
Q2 		$6.47M Sell
115,300
-7,700
-6% -$437K 0.02% 932
2023
Q1 		$5.56M Sell
123,000
-8,800
-7% -$427K 0.02% 824
2022
Q4 		$5.36M Hold
131,800
– – 0.02% 809
2022
Q3 		$8.61M Buy
+131,800
New +$9.55M 0.04% 493

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Squarepoint's CRSP Position: Q1 2026 in Review

Squarepoint reduced its CRISPR Therapeutics (CRSP) stake by 74% in Q1 2026, selling an estimated $22.5M and leaving 153,575 shares worth $7.31M. The position accounts for 0.01% of the portfolio, ranked #1256.

Squarepoint first reported a position in CRSP in Q1 2018 and has held it in 23 quarters since. The position peaked at $30.5M in Q4 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Squarepoint held 153,575 shares of CRISPR Therapeutics worth $7.31M as of Q1 2026.
  • Squarepoint sold 427,533 CRISPR Therapeutics shares in Q1 2026, an estimated $22.5M.
  • CRISPR Therapeutics made up 0.01% of Squarepoint's portfolio in Q1 2026, its #1256 holding.
  • Squarepoint first reported a position in CRISPR Therapeutics in Q1 2018 and has held it in 23 quarters since.
  • Squarepoint's CRISPR Therapeutics position peaked at $30.5M in Q4 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.